Erasca, Inc. (ERAS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | (m) | |
| Stock-based compensation | 29.85M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -302.68M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $29.85M | $-302.68M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $26.65M | $-293.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $24.90M | $-140.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $25.38M | $-144.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $26.06M | $-146.71M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $26.84M | $-176.37M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $26.97M | $-179.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $26.80M | $-177.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $26.40M | $-175.16M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $26.23M | $-143.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $26.23M | $-141.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $25.48M | $-245.73M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $24.47M | $-248.03M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $22.51M | $-247.97M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $20.11M | $-247.45M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $17.61M | $-140.42M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $15.40M | $-149.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $11.98M | $-141.78M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $8.33M | $-124.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $797.00K | $-109.25M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |